Hormone receptor-positive breast cancer accounts for approximately 70 percent of all breast cancer diagnoses globally, making hormone therapy for breast cancer after surgery the most commonly used systemic treatment in oncology. For decades, the standard was clear: tamoxifen or an aromatase inhibitor, taken for five to ten years, with the expectation that it would prevent recurrence. That picture has changed substantially. New drug classes, molecular biomarkers that guide therapy selection, extended treatment duration evidence, and combination approaches that overcome endocrine resistance have all reshaped how hormone therapy for breast cancer after surgery is practised in 2025 and 2026.
For international patients seeking access to these advances, India's leading oncology centres are delivering the full spectrum of current endocrine therapy at a fraction of Western costs. This guide covers what has changed, what the evidence shows for each advance, and how these options are accessed in India.
The Foundation: Standard Hormone Therapy After Surgery
Before understanding what is new, it helps to be clear on what the standard foundation of hormone therapy for breast cancer after surgery looks like, because the advances build on it rather than replace it.
How Standard Endocrine Therapy Works
Hormone receptor-positive (HR-positive) breast cancer cells carry oestrogen receptors (ER) or progesterone receptors (PR) on their surface and depend on oestrogen signalling to grow and divide. Standard endocrine therapies work by either blocking this signal or eliminating the oestrogen that drives it.
The primary agents are:
-
Tamoxifen: A selective oestrogen receptor modulator (SERM) that blocks ER in breast tissue while partially activating it in bone and uterus. Standard for premenopausal women and an alternative for postmenopausal women unable to take aromatase inhibitors. Given for five to ten years post-surgery.
-
Aromatase inhibitors (AIs): Anastrozole, letrozole, and exemestane suppress oestrogen synthesis by blocking the aromatase enzyme. Standard for postmenopausal women and for premenopausal women when combined with ovarian function suppression. Ten years of AI therapy reduces long-term recurrence risk versus five years.
-
Ovarian function suppression (OFS): Goserelin or leuprolide injections suppress ovarian oestrogen production in premenopausal women. OFS combined with AI or tamoxifen is superior to tamoxifen alone in high-risk premenopausal patients per the SOFT and TEXT trial data.
Standard endocrine therapy is the most effective tool for preventing late recurrence (which continues beyond five years in HR-positive disease), but resistance develops in a proportion of patients, which is where the new advances matter most.
Advance 1: CDK4/6 Inhibitors in Adjuvant and Advanced Settings
CDK4/6 inhibitors have redefined the standard of care for HR-positive breast cancer since their introduction and continue to generate practice-changing data in 2025 and 2026.
What CDK4/6 Inhibitors Do
CDK4/6 inhibitors block the cyclin-dependent kinases 4 and 6, which drive cells from the growth phase into DNA replication. Blocking these enzymes essentially pauses cancer cell division. Combined with endocrine therapy, they produce significantly longer disease control than endocrine therapy alone.
Three CDK4/6 inhibitors are FDA-approved: palbociclib, ribociclib, and abemaciclib. A 2025 meta-analysis published in ScienceDirect (April 2026) analysed reconstructed individual patient data from phase 3 trials and confirmed that CDK4/6 inhibitors combined with endocrine therapy significantly improved both progression-free survival and overall survival versus endocrine monotherapy. Importantly, only abemaciclib (HR 0.79, p=0.0031) and ribociclib (HR 0.73, p<0.0001) showed significant overall survival benefits; palbociclib did not reach statistical significance for OS (HR 0.89, p=0.0920).
Adjuvant Abemaciclib for High-Risk Early Breast Cancer
Abemaciclib is now approved in the adjuvant setting (after surgery) for node-positive, HR-positive, HER2-negative early breast cancer with high-risk features. The monarchE trial confirmed that two years of abemaciclib combined with standard endocrine therapy reduces the risk of distant recurrence meaningfully versus endocrine therapy alone. This is one of the most significant expansions of hormone therapy for breast cancer after surgery in recent years.
At India's leading breast oncology centres, abemaciclib plus aromatase inhibitor or tamoxifen is available for eligible high-risk early breast cancer patients, at costs substantially below what the same combination costs in the USA or UK.
Advance 2: Oral Selective Estrogen Receptor Degraders (SERDs)
The second major category of advance in hormone therapy for breast cancer after surgery is the oral SERD class, which has moved from single injectable fulvestrant to multiple oral options with superior bioavailability and the ability to address ESR1-mutated endocrine resistance.
Why New SERDs Matter
ESR1 mutations in the oestrogen receptor gene develop in HR-positive breast cancer under the selection pressure of aromatase inhibitor therapy. These mutations make the ER constitutively active independent of oestrogen, enabling cancer cells to continue growing despite oestrogen suppression. Standard aromatase inhibitors are rendered ineffective by ESR1 mutations; SERDs that degrade the receptor entirely rather than just blocking it retain activity against ESR1-mutated disease.
Elacestrant
Elacestrant (Orserdu) is the first oral SERD FDA-approved for HR-positive, HER2-negative metastatic breast cancer with ESR1 mutations after prior endocrine therapy. The EMERALD phase III trial confirmed clinically meaningful improvement in progression-free survival versus standard endocrine therapy, with the benefit particularly pronounced in patients with confirmed ESR1 mutations.
Imlunestrant
Imlunestrant, a next-generation oral SERD, demonstrated activity in the EMBER study and showed clinically meaningful benefit in the phase III EMBER-3 trial published in the New England Journal of Medicine in 2025. At ASCO 2025, results showed imlunestrant with or without abemaciclib in advanced breast cancer improved outcomes in ESR1-mutated and broader HR-positive populations.
ctDNA-Guided ESR1 Monitoring
One of the most clinically significant 2026 developments is the emergence of ctDNA (circulating tumour DNA) monitoring to detect ESR1 mutations before radiographic progression. A June 2026 narrative review in Diagnostics confirmed that serial ctDNA monitoring detecting emergent ESR1 mutations can trigger early therapeutic modification and extend endocrine-based disease control by approximately five to seven months compared to switching only at clinical progression (PADA-1 and SERENA-6 data).
For international patients, this means that the best oncology Hospitals now incorporate liquid biopsy-based ESR1 monitoring into the post-surgery surveillance pathway.
Advance 3: Targeting the PIK3CA and AKT Pathways
Resistance to standard endocrine therapy is frequently driven by mutations in the PI3K-AKT-mTOR pathway, which provides an alternative survival signal that breast cancer cells use to bypass oestrogen-receptor-dependent growth.
Alpelisib for PIK3CA-Mutated Disease
Alpelisib (Piqray) is a PIK3CA-specific inhibitor approved for HR-positive, HER2-negative advanced breast cancer with PIK3CA mutations, combined with fulvestrant. PIK3CA mutations occur in approximately 40 percent of HR-positive breast cancers. The SOLAR-1 trial confirmed meaningful progression-free survival improvement versus fulvestrant alone in the PIK3CA-mutated group.
Identifying PIK3CA mutation status before starting alpelisib requires genomic testing either from tissue biopsy or liquid biopsy. At India's leading oncology centres, next-generation sequencing panels that include PIK3CA are performed as part of the standard biomarker workup.
Capivasertib for AKT Pathway
Capivasertib combined with fulvestrant is approved for HR-positive, HER2-negative advanced breast cancer with AKT pathway alterations (PIK3CA, AKT1, or PTEN alterations), after prior endocrine therapy. The CAPItello-291 trial confirmed overall survival benefit in the biomarker-selected population. This broadens the targetable population beyond PIK3CA to include additional PI3K pathway mutations.
Everolimus and mTOR Combination
Everolimus combined with exemestane (an aromatase inhibitor) remains relevant for HR-positive breast cancer after prior AI therapy. A real-world multicenter study from Turkey published in early 2026 found that patients continuing endocrine-based therapy including mTOR combinations after CDK4/6 inhibitor progression lived significantly longer than those who received chemotherapy, reinforcing that endocrine-based strategies should be prioritised before transitioning to chemotherapy even at later treatment lines.
Advance 4: Extended and Personalised Endocrine Therapy Duration
A key ongoing area in hormone therapy for breast cancer after surgery is determining who benefits from extended endocrine therapy and who can safely stop at five years.
The Extended Endocrine Therapy Evidence
Multiple trials confirm that extending aromatase inhibitor therapy from five to ten years reduces late recurrence risk in higher-risk patients. The NSABP B-42, DATA, and MA.17R trials collectively support ten years of endocrine therapy for women with node-positive disease or other high-risk features, where the absolute benefit of the additional five years outweighs the side-effect burden.
Genomic Testing to Personalise Duration
Genomic risk scores including Oncotype DX, MammaPrint, and Prosigna help determine who has a sufficiently high late recurrence risk to benefit from extended therapy, and who can safely stop at five years. These tests analyse the molecular biology of the tumour rather than relying solely on clinical factors. At India's leading breast oncology centres, these genomic assays are available and used to guide extended therapy decisions, a level of personalisation not available at many centres in the countries from which international patients travel.
Accessing Advanced Hormone Therapy for Breast Cancer in India
India's leading NABH and JCI-accredited breast oncology centres offer the complete spectrum of current hormone therapy for breast cancer after surgery, including:
-
Adjuvant abemaciclib plus aromatase inhibitor for high-risk early breast cancer
-
Oral SERDs including elacestrant for ESR1-mutated advanced disease
-
PIK3CA inhibitor alpelisib with fulvestrant for PIK3CA-mutated cases
-
AKT pathway inhibitor capivasertib for broader PI3K pathway alterations
-
ctDNA-based ESR1 monitoring at select advanced oncology centres
-
Genomic profiling with Oncotype DX and MammaPrint for personalised duration decisions
-
Extended aromatase inhibitor therapy for ten years in high-risk patients
Cost of hormone therapy for breast cancer in India is 60 to 80 percent lower than in the USA or UK. A year of abemaciclib in the USA costs approximately USD 120,000. In India, the same drug is available through generic and branded routes at costs accessible to international patients at a fraction of this figure. Aromatase inhibitors and tamoxifen are available generically in India at minimal cost.
For international patients who have had surgery abroad and are seeking to continue or optimise their adjuvant endocrine therapy, Karetrip identifies the most appropriate breast oncology centre in India based on the patient's specific receptor profile, prior treatment history, and the specific agents available at the proposed centre.
How Karetrip Supports International Breast Cancer Patients
The right hormone therapy for breast cancer after surgery depends on the receptor profile, molecular subtype, risk category, and any resistance mutations that have developed. Karetrip reviews each patient's pathology report and prior treatment history before recommending a breast oncology centre in India, confirming that the proposed centre has access to the specific agents and the genomic testing required for the patient's clinical situation.
From pre-travel record review and medical visa coordination, through accommodation near the treating hospital and coordination of adjuvant treatment initiation, Karetrip manages the complete international patient journey for breast cancer hormone therapy in India.
Chat with our Medical care assistant, RUA, for quick guidance and support and take the first step toward accessing personalised hormone therapy for breast cancer after surgery in India.